Pharmacology of Nonsteroidal Antiinflammatory Drugs and Opioids

ABSTRACT

Chronic pain affects up to 50 million Americans every day. Traditional treatment has included acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), or opioids. The combination of NSAIDs and opioids can provide effective treatment for up to 90% of patients with chronic pain, but the NSAIDs have the potential for significant, even life-threatening side effects. Additionally, the nonselective cyclooxygenase inhibitors with 16,000 deaths per year in the United States might not be any safer. The opioids are great for short-term pain, but may need to be adjusted or changed frequently due to the development of tolerance. Understanding of the mechanism of opioids and NSAIDs has improved greatly over the past decade, but is still incomplete.

KEYWORDS

NSAIDs - opioids - analgesics - mechanisms - pharmacology

REFERENCES

• 1 Dubois M Y, Gallagher R M, Lippe P M. Pain medicine position paper.  Pain Med. 2009;  10(6) 972-1000
• 2 Breivik H, Cherny N, Collett B et al.. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes.  Ann Oncol. 2009;  20(8) 1420-1433 , 10.1093/annonc/mdp001
• 3 Tauberer J. A civic project to track Congress. Available at: http://www.govtrack.us/congress/bill.xpd?bill=h111-756&tab=committees Accessed October 3, 2009
• 4 Ueberall M, Mueller-Schwefe G. 705 individual treatment targets in chronic pain management.  Eur J Pain. 2006;  10 S184
• 5 Abeles A M, Pillinger M H, Solitar B M, Abeles M. Narrative review: the pathophysiology of fibromyalgia.  Ann Intern Med. 2007;  146(10) 726-734
• 6 Merskey H, Bogduk N Pain 1. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle; IASP Press 1994: 209-214
• 7 Fields R D. New culprits in chronic pain.  Sci Am. 2009;  301(5) 50-57
• 8 Woodcock J, Witter J, Dionne R A. Stimulating the development of mechanism-based, individualized pain therapies.  Nat Rev Drug Discov. 2007;  6(9) 703-710
• 9 Levy M H. Pharmacologic treatment of cancer pain.  N Engl J Med. 1996;  335(15) 1124-1132
• 10 Smyth E M, FitzGerald G A. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. In: Katzung BG, Masters SB, Trevor AJ Basic & Clinical Pharmacology. 11th ed. New York; McGraw-Hill 2009: 313-330
• 11 Yaksh T L, Dirig D M, Malmberg A B. Mechanism of action of nonsteroidal anti-inflammatory drugs.  Cancer Invest. 1998;  16(7) 509-527
• 12 Wallace J L, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs.  Trends Pharmacol Sci. 1994;  15(11) 405-406
• 13 Wallace J L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?.  Physiol Rev. 2008;  88(4) 1547-1565
• 14 Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy.  Am J Med. 1998;  105(1B, 1B) 31S-38S
• 15 Lockrey G J. Management of peptic ulcer disease in older people.  Aust J Hosp Pharm. 1999;  29 45-50
• 16 Gislason G H, Jacobsen S, Rasmussen J N et al.. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.  Circulation. 2006;  113(25) 2906-2913
• 17 Jensen B L, Kurtz A. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake.  Kidney Int. 1997;  52(5) 1242-1249
• 18 Kömhoff M, Grone H J, Klein T, Seyberth H W, Nüsing R M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function.  Am J Physiol. 1997;  272(4 Pt 2) F460-F468
• 19 Silbernagl S, Lang F. Color Atlas of Pathophysiology. Stuttgart and New York; Thieme Medical Publishing 2000: 118
• 20 Sankaran D, Bankovic-Calic N, Ogborn M R, Crow G, Aukema H M. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease.  Am J Physiol Renal Physiol. 2007;  293(3) F821-F830
• 21 Hao C M, Breyer M D. Physiological regulation of prostaglandins in the kidney.  Annu Rev Physiol. 2008;  70 357-377
• 22 Sankaran D, Bankovic-Calic N, Ogborn M R, Crow G, Aukema H M. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease.  Am J Physiol Renal Physiol. 2007;  293(3) F821-F830
• 23 David Josephy P. The molecular toxicology of acetaminophen.  Drug Metab Rev. 2005;  37(4) 581-594 , 10.1080/03602530500205200
• 24 Anderson B J. Paracetamol (acetaminophen): mechanisms of action.  Paediatr Anaesth. 2008;  18(10) 915-921
• 25 Davies N M, Good R L, Roupe K A, Yáñez J A. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?—Not as easy as 1, 2, 3.  J Pharm Pharm Sci. 2004;  7(2) 217-226
• 26 Chandrasekharan N V, Dai H, Roos K L et al.. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.  Proc Natl Acad Sci U S A. 2002;  99(21) 13926-13931 , [PMID: 12242329]
• 27 Mackowiak P A. Brief history of antipyretic therapy.  Clin Infect Dis. 2000;  31(Suppl 5) S154-S156
• 28 Furst D, Ulrich R, Varkey-Altamirano C. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout. In: Katzung BG, Masters SB, Trevor AJ Basic & Clinical Pharmacology. 11th ed. New York; McGraw-Hill 2009: 621-642
• 29 Pearson T A, Blair S N, Daniels S R American Heart Association Science Advisory and Coordinating Committee et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases.  Circulation. 2002;  106(3) 388-391
• 30 Giovannucci E, Rimm E B, Stampfer M J, Colditz G A, Ascherio A, Willett W C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.  Ann Intern Med. 1994;  121(4) 241-246
• 31 Glasgow J F. Reye's syndrome: the case for a causal link with aspirin.  Drug Saf. 2006;  29(12) 1111-1121
• 32 Hawkey C J, Karrasch J A, Szczepañski L et al.. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.  N Engl J Med. 1998;  338(11) 727-734
• 33 Stillman M J, Stillman M T. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway.  Geriatrics. 2007;  62(2) 26-34
• 34 Przewlocki R, Przewlocka B. Opioids in neuropathic pain.  Curr Pharm Des. 2005;  11(23) 3013-3025
• 35 Busch-Dienstfertig M, Stein C. Opioid receptors and opioid peptide-producing leukocytes in inflammatory pain—basic and therapeutic aspects.  Brain Behav Immun. 2010;  24(5) 683-694
• 36 Stein C, Lang L J. Peripheral mechanisms of opioid analgesia.  Curr Opin Pharmacol. 2009;  9(1, Issue 1) 3-8
• 37 O'Connor A B, Dworkin R H. Treatment of neuropathic pain: an overview of recent guidelines.  Am J Med. 2009;  122(10, Suppl) S22-S32
• 38 Evans R M, You H, Hameed S et al.. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation.  J Biol Chem. 2010;  285(2) 1032-1040
• 39 Marker C L, Luján R, Loh H H, Wickman K. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids.  J Neurosci. 2005;  25(14) 3551-3559
• 40 Eippert F, Bingel U, Schoell E D et al.. Activation of the opioidergic descending pain control system underlies placebo analgesia.  Neuron. 2009;  63(4) 533-543
• 41 Cox B M, Chavkin C, Christie M J et al.. Opioid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. London; IUPHAR Media Ltd. 2000: 321-333
• 42 Holzer P. Opioid receptors in the gastrointestinal tract.  Regul Pept. 2009;  155(1-3) 11-17
• 43 Corbett A D, Henderson G, McKnight A T, Paterson S J. 75 years of opioid research: the exciting but vain quest for the Holy Grail.  Br J Pharmacol. 2006;  147(Suppl 1) S153-S162 , 10.1038/sj.bjp.0706435 PMID 16402099
• 44 Aggrawal A. Opium: the king of narcotics. In: Aggrawal A Narcotic Drugs. New Delhi; New Delhi National Book Trust 1995: 161
• 45 Ackley M A, Baldwin S A, King A E. Adenosine contributes to mu-opioid synaptic inhibition in rat substantia gelatinosa in vitro.  Neurosci Lett. 2005;  376(2) 102-106
• 46 Walsh S L, Chausmer A E, Strain E C, Bigelow G E. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.  Psychopharmacology (Berl). 2008;  196(1) 143-155
• 47 Bodnar R J. Endogenous opiates and behavior.  Peptides. 2009;  30(12) 2432-2479 , doi:10.1016/j.peptides.2009.09.027
• 48 Abramow-Newerly M, Roy A A, Nunn C, Chidiac P. RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins.  Cell Signal. 2006;  18(5) 579-591
• 49 Khafizov K, Lattanzi G, Carloni P. G protein inactive and active forms investigated by simulation methods.  Proteins. 2009;  75(4) 919-930
• 50 Pravetoni M, Wickman K. G protein gated potassium channels (GIRK/ Kir3) mediate the motor stimulatory effects of opiates.  FASEB J. 2008;  22 712
• 51 Mao J. Opioid-induced abnormal pain sensitivity.  Curr Pain Headache Rep. 2006;  10(1) 67-70
• 52 Angst M S, Clark J D. Opioid-induced hyperalgesia: a qualitative systematic review.  Anesthesiology. 2006;  104(3) 570-587
• 53 Angst M S, Koppert W, Pahl I, Clark D J, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal.  Pain. 2003;  106(1-2) 49-57
• 54 Lewis S S, Hutchinson M R, Rezvani N et al.. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.  Neuroscience. 2010;  165(2) 569-583
• 55 Ballantyne J C, Shin N S. Efficacy of opioids for chronic pain: a review of the evidence.  Clin J Pain. 2008;  24(6) 469-478
• 56 Price D D, Mayer D J, Mao J et al.. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance.  J Pain Symptom Manage. 2000;  19(1, Suppl) 7-11
• 57 Leppert W. The role of methadone in opioid rotation-a Polish experience.  Support Care Cancer. 2009;  17(5) 607-612
• 58 Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature.  J Opioid Manag. 2008;  4(4) 213-250
• 59 Thomas J, Karver S, Cooney G A et al.. Methylnaltrexone for opioid-induced constipation in advanced illness.  N Engl J Med. 2008;  358(22) 2332-2343
• 60 Holzer P. New approaches to the treatment of opioid-induced constipation.  Eur Rev Med Pharmacol Sci. 2008;  12(Suppl 1) 119-127
• 61 Wang J J, Ho S T, Tzeng J I. Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects.  Reg Anesth Pain Med. 1998;  23(5) 479-484
• 62 Roberts L, Finch P, Pullan P et al.. Sex hormone suppression by intrathecal opioids: a prospective study.  Clin J Pain. 2002;  8(3) 144-148
• 63 Smith H S. Opioid metabolism.  Mayo Clin Proc. 2009;  84(7) 613-624
• 64 Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer.  Pain Pract. 2007;  7(4) 352-356
• 65 Raffa R. Pharmacological aspects of successful long-term analgesia.  Clin Rheumatol. 2006;  25(Suppl 1) S9-S15 , 10.1007/s10067-006-0201-x
• 66 de Leon-Casasola O A, Lema M J. Postoperative epidural opioid analgesia: what are the choices?.  Anesth Analg. 1996;  83(4) 867-875
• 67 Manfredi P L, Houde R W. Prescribing methadone, a unique analgesic.  J Support Oncol. 2003;  1(3) 216-220
• 68 Varvel J R, Shafer S L, Hwang S S, Coen P A, Stanski D R. Absorption characteristics of transdermally administered fentanyl.  Anesthesiology. 1989;  70(6) 928-934
• 69 Hutchison L, O'Brien C E. Changes in pharmacokinetics and pharmacodynamics in the elderly patient.  J Pharm Pract. 2007;  20(1) 4-12
• 70 Fallon M, Hanks G, Cherny N. Principles of control of cancer pain.  BMJ. 2006;  332(7548) 1022-1024
• 71 Lussier D, Huskey A G, Portenoy R K. Adjuvant analgesics in cancer pain management.  Oncologist. 2004;  9(5) 571-591 , 10.1634/theoncologist.9-5-57
• 72 PharmacyChecker.com LLC .Compare drug prices. http://Available at: http: www.pharmacychecker.com Accessed October 10, 2009